Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential

Sela-Passwell, Netta; Kikkeri, Raghavendra; Dym, Orly; Rozenberg, Haim; Margalit, Raanan; Arad‐Yellin, Rina; Eisenstein, Miriam; Brenner, Ori; Shoham, Tsipi; Danon, Tamar; Shanzer, Abraham; Sagi, Irit

doi:10.1038/nm.2582

Cited by 142 publications

(124 citation statements)

References 36 publications

Supporting

Mentioning

120

Contrasting

Order By: Relevance

“…As a result, broad-spectrum hydroxamates failed in cancer clinical trials due to their low overall efficacy and side effects (13). Alternatively, antibody-based MMP inhibitors are emerging as both research tools and potential therapeutic agents (10,(17)(18)(19)(20)(21) because of (i) high affinity and specificity due to the large antigen-antibody interaction area and multiple complementarity-determining regions (CDRs), (ii) long half-life and well-defined action mechanisms, (iii) low immunogenicity and toxicity, and (iv) multiple MMPs potentially targetable by antibodies (9).…”

mentioning

confidence: 99%

Active-site MMP-selective antibody inhibitors discovered from convex paratope synthetic libraries

Nam

Rodríguez

Remacle

et al. 2016

Proc. Natl. Acad. Sci. U.S.A.

110

View full text Add to dashboard Cite

Proteases are frequent pharmacological targets, and their inhibitors are valuable drugs in multiple pathologies. The catalytic mechanism and the active-site fold, however, are largely conserved among the protease classes, making the development of the selective inhibitors exceedingly challenging. In our departure from the conventional strategies, we reviewed the structure of known camelid inhibitory antibodies, which block enzyme activities via their unusually long, convex-shaped paratopes. We synthesized the human Fab antibody library (over 1.25 × 10 9 individual variants) that carried the extended, 23-to 27-residue, complementarity-determining region (CDR)-H3 segments. As a proof of principle, we used the catalytic domain of matrix metalloproteinase-14 (MMP-14), a promalignant protease and a drug target in cancer, as bait. In our screens, we identified 20 binders, of which 14 performed as potent and selective inhibitors of MMP-14 rather than as broad-specificity antagonists. Specifically, Fab 3A2 bound to MMP-14 in the vicinity of the active pocket with a high 4.8 nM affinity and was similarly efficient (9.7 nM) in inhibiting the protease cleavage activity. We suggest that the convex paratope antibody libraries described here could be readily generalized to facilitate the design of the antibody inhibitors to many additional enzymes. family members control various physiological and pathological processes. Multiple diseases are associated with altered MMP expression and aberrant proteolysis, including cancer (1), wound healing (2), inflammatory diseases (3, 4), neurological pain (5, 6), and hypertension (7). There is consensus among researchers that the individual MMPs are promising drug targets in diversified pathologies and that inhibitor specificity is required for selective and successful MMP therapies (8-10).However, achieving target specificity and selectivity in small-molecule MMP inhibitors is remarkably challenging (11,12). Because the catalytic mechanism and catalytic domain fold are conserved among the MMP/ADAM (a disintegrin and metalloproteinase)/ ADAMTS (ADAM with thrombospondin motifs) superfamily members, the available small-molecule inhibitors (most frequently, active-site zinc-chelating hydroxamates) target multiple proteinases, resulting in off-target side effects (8,(12)(13)(14). This aspect is problematic, given that some MMPs (e.g., MMP-14) are always protumorigenic, whereas some other MMPs are antitumorigenic in certain cancer microenvironments (15, 16). As a result, broad-spectrum hydroxamates failed in cancer clinical trials due to their low overall efficacy and side effects (13). Alternatively, antibody-based MMP inhibitors are emerging as both research tools and potential therapeutic agents (10, 17-21) because of (i) high affinity and specificity due to the large antigen-antibody interaction area and multiple complementarity-determining regions (CDRs), (ii) long half-life and well-defined action mechanisms, (iii) low immunogenicity and toxicity, and (iv) multiple MMPs potentially targe...

show abstract

mentioning

confidence: 99%

Active-site MMP-selective antibody inhibitors discovered from convex paratope synthetic libraries

Nam

Rodríguez

Remacle

et al. 2016

Proc. Natl. Acad. Sci. U.S.A.

110

View full text Add to dashboard Cite

show abstract

“…An alternative approach has involved the generation of humanized monoclonal antibodies and successful inhibition of MT1-MMP activity has been reported in tumor cells, with a concurrent decrease in the activation of pro-MMP-2 [173,174]. An animal model of inflammatory bowel disease has been utilized to demonstrate the efficacy of an antibody for MMP-2 and 9, but applications to vascular remodeling have not been pursued [175]. An MMP-9-specific antibody has also been developed and proved to effectively inhibit hematopoietic cell mobilization in nonhuman primates, but further investigation into human trials has not occurred [176].…”

Section: Targets To Promote Plaque Stabilizationmentioning

confidence: 99%

Multidimensional Contribution of Matrix Metalloproteinases to Atherosclerotic Plaque Vulnerability: Multiple Mechanisms of Inhibition to Promote Stability

Ruddy¹,

Ikonomidis²,

Jones³

2016

J Vasc Res

View full text Add to dashboard Cite

The prevalence of atherosclerotic disease continues to increase, and despite significant reductions in major cardiovascular events with current medical interventions, an additional therapeutic window exists. Atherosclerotic plaque growth is a complex integration of cholesterol penetration, inflammatory cell infiltration, vascular smooth muscle cell (VSMC) migration, and neovascular invasion. A family of matrix-degrading proteases, the matrix metalloproteinases (MMPs), contributes to all phases of vascular remodeling. The contribution of specific MMPs to endothelial cell integrity and VSMC migration in atherosclerotic lesion initiation and progression has been confirmed by the increased expression of these proteases in plasma and plaque specimens. Endogenous blockade of MMPs by the tissue inhibitors of metalloproteinases (TIMPs) may attenuate proteolysis in some regions, but the progression of matrix degeneration suggests that MMPs predominate in atherosclerotic plaque, precipitating vulnerability. Plaque neovascularization also contributes to instability and, coupling the known role of MMPs in angiogenesis to that of atherosclerotic plaque growth, interest in targeting MMPs to facilitate plaque stabilization continues to accumulate. This article aims to review the contributions of MMPs and TIMPs to atherosclerotic plaque expansion, neovascularization, and rupture vulnerability with an interest in promoting targeted therapies to improve plaque stabilization and decrease the risk of major cardiovascular events.

show abstract

“…Immunizing mice with synthetic compounds that resemble the catalytic zinc-histidine complex in the active site and the conformational epitopes on the surface of MMP-2 and MMP-9 makes it possible to produce monoclonal antibodies (SDS3 and SDS4) that are highly specific and function by mimicking the binding of TIMPS. Using this strategy, MMP-2 and -9 were both selectively inhibited by monoclonal antibodies in a mouse model of inflammatory bowel disease but clearly these reagents could be extremely useful for the treatment of cancers in which MMP-2 and MMP-9 play a role [80].…”

Section: Using Antibodies To Selectively Target Mmpsmentioning

confidence: 99%

New approaches to selectively target cancer-associated matrix metalloproteinase activity

Tauro

McGuire

Lynch

2014

Cancer Metastasis Rev

View full text Add to dashboard Cite

Heightened matrix metalloproteinase (MMP) activity has been noted in the context of the tumor microenvironment for many years, and causal roles for MMPs have been defined across the spectrum of cancer progression. This is primarily due to the ability of the MMPs to process extracellular matrix (ECM) components and to regulate the bioavailability/activity of a large repertoire of cytokines and growth factors. These characteristics made MMPs an attractive target for therapeutic intervention but notably clinical trials performed in the 1990s did not fulfill the promise of preclinical studies. The reason for the failure of early MMP inhibitor (MMPI) clinical trials that are multifold but arguably principal among them was the inability of early MMP-based inhibitors to selectively target individual MMPs and to distinguish between MMPs and other members of the metzincin family. In the decades that have followed the MMP inhibitor trials, innovations in chemical design, antibody-based strategies, and nanotechnologies have greatly enhanced our ability to specifically target and measure the activity of MMPs. These advances provide us with the opportunity to generate new lines of highly selective MMPIs that will not only extend the overall survival of cancer patients, but will also afford us the ability to utilize heightened MMP activity in the tumor microenvironment as a means by which to deliver MMPIs or MMP activatable prodrugs.

show abstract

Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential

Cited by 142 publications

References 36 publications

Active-site MMP-selective antibody inhibitors discovered from convex paratope synthetic libraries

Active-site MMP-selective antibody inhibitors discovered from convex paratope synthetic libraries

Multidimensional Contribution of Matrix Metalloproteinases to Atherosclerotic Plaque Vulnerability: Multiple Mechanisms of Inhibition to Promote Stability

New approaches to selectively target cancer-associated matrix metalloproteinase activity

Contact Info

Product

Resources

About